Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads…

| More on:
Woman with headphones on relaxing and looking at her phone happily.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yesterday, we got one of the first earnings reports of the season from a major blue chip share. That blue chip share was healthcare stock CSL Ltd (ASX: CSL). We discussed all of the major details at the time, so today, let's dig into the new CSL dividend.

If you missed our initial report, let's quickly go over the highlights in a nutshell.

For the six months to 31 December, CSL reported a 5% rise in revenues (on a constant currency basis) to US$8.48 billion. Net profits after tax were up 7% to US$2.04 billion.

Even so, investors didn't seem to know how to take the results. Upon market open yesterday, CSL shares initially lifted about 1.6%, but finished the day down 4.95% at $256.96 a share.

But let's talk dividends.

The latest CSL dividend

Yesterday, CSL revealed that its next interim dividend would come in at US$1.30 per share. The final amount in Australian dollars has yet to be determined, but the company has told investors to expect around $2.08 per share in the local currency. Like all of the company's payouts last year, this dividend will come unfranked.

This latest payout represents a 9.24% rise on last year's interim dividend of US$1.19 per share.

CSL stock will trade ex-dividend for this payout on 10 March. Investors who have CSL shares to their name at the market close on 9 March can then expect the dividend paycheque to arrive on 9 April.

CSL does technically operate a dividend reinvestment plan (DRP). However, this plan isn't active for this payment, so shareholders have no option other than to receive the dividend in cash.

Together with the final dividend of US$1.45 ($2.17), the latest interim dividend takes CSL's full-year payouts to US$2.75 per share, or $4.38, at current exchange rates.

That gives CSL a forward dividend yield of 1.7% at yesterday's closing price. CSL currently trades on a trailing yield of 1.54%.

CSL share price snapshot

CSL shares have had a rough 12 months, even before yesterday's selloff. As it currently stands, the healthcare giant is nursing an 11.47% loss over the past 12 months. That includes an 8.6% drop in 2025 to date.

The company has still yet to reclaim its pre-COVID 2020 high of over $340 a share.

As it stands today, CSL shares are trading on a market capitalisation of $124.4 billion, with a price-to-earnings (P/E) ratio of 29.65.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why are 4DMedical shares in a trading halt today?

The company is looking to raise fresh capital.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech's shares are up strongly on good news out of the US

The addressable market for this newly approved software is huge.

Read more »